Table 1.
Clinical characteristics of the discovery cohort
| Good prognosisa | Poor prognosisa | |
|---|---|---|
| n | 35 | 35 |
| Age (mean ± sd) | 62.7 ± 5.6 | 65 ± 6.6 |
| Pretreatment PSA (ng/ml) | 6.86 ± 3.4 | 28.3 ± 22.3 |
| Stage (path. T) | ||
| pT2 | 35 | 0 |
| pT3a | 0 | 3 |
| pT3b | 0 | 31 |
| pT4 | 0 | 1 |
| Gleason score | ||
| 3 + 3 | 15 | 0 |
| 3 + 4 | 17 | 6 |
| 4 + 3 | 3 | 15 |
| 4 + 4 | 0 | 4 |
| 4 + 5 | 0 | 7 |
| 5 + 4 | 0 | 3 |
aGood prognosis defined as an organ-confined disease (pT2) and lack of biochemical (PSA-based) recurrence (BCR) for at least 5 years. Poor prognosis defined as systemic presence of metastatic disease, indicated by recurrence within 3 years and no response to local radiation therapy